PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study

BACKGROUND: Recaticimab (SHR-1209, a humanized monoclonal antibody against PCSK9) showed robust LDL-C reduction in healthy volunteers. This study aimed to further assess the efficacy and safety of recaticimab in patients with hypercholesterolemia. METHODS: In this randomized, double-blind, placebo-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Mingtong, Zhu, Xiaoxue, Wu, Junyan, Zhang, Yuling, Zhao, Dong, Wang, Xuhong, Ding, Yanhua, Cao, Yu, Li, Chengqian, Hu, Wei, Sheng, Jianlong, Luo, Zhu, Zheng, Zeqi, Hu, Jinfang, Liu, Jianying, Zhou, Xiaoyang, Shen, Aizong, Ding, Xiaomei, Zhang, Yongdong, Zhao, Yonggang, Li, Yijing, Zhong, Sheng, An, Shimin, Zou, Jianjun, Yan, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763618/
https://www.ncbi.nlm.nih.gov/pubmed/35039035
http://dx.doi.org/10.1186/s12916-021-02208-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763618/
https://www.ncbi.nlm.nih.gov/pubmed/35039035
http://dx.doi.org/10.1186/s12916-021-02208-w

Ejemplares similares